Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS APPLAUDS JAPANESE GOVERNMENT NEW REGULATION SUPPORTING DIAGNOSIS, SUCH AS FFR, BEFORE TREATMENT OF CORONARY STENOSIS

24 April 2018

Quebec City, Quebec, April 24, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) applauds Japan’s Ministry of Health, Labor and Welfare (“MHLW”) on its new regulation requiring the evaluation of any coronary stenosis prior to its treatment, specifically mentioning Fractional Flow Reserve (“FFR”) as a preferred assessment method. The MHLW recently revised medical…

Read more

OPSENS REPORTS Q2 2018 RESULTS – CONSOLIDATED PRODUCT SALES UP 44%

12 April 2018

Quebec City, Quebec, April 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter ended February 28, 2018. Highlights Consolidated product sales reached $5,352,000 compared with $3,710,000 for the same period last year, an increase of $1,642,000 or 44,3%; Fractional Flow Reserve (“FFR”) revenues reached $3,313,000…

Read more

OPSENS’ TECHNOLOGY GRANTED FDA APPROVAL IN ABIOMED’S IMPELLA CARDIAC PUMP®

3 April 2018

Quebec City, Quebec, April 3, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces that the integration of Opsens’ technology, within the Impella Cardiac Pump® (“Impella CP®“), marketed by its client Abiomed, Inc. (” Abiomed “), is approved by the US Food and Drug Administration (” FDA “). This news follows the US$6 million…

Read more

84th German Cardiac Society Annual Meeting in Mannheim 2018

30 March 2018

Opsens sponsored Symposium: Clinical value of FFR and adenosine-free alternatives in the cathlab Our Distributor, Bisping Medizintechnik GmbH will showcase the Opsens technology at German Cardiac Societies Annual Meeting in Mannheim, Germany, from April 4th to 7th, 2018. They will show the innovative, fast and easy-to-use OptoMonitor FFR system together with the best-in-class optical OptoWire…

Read more

VISIT OPSENS MEDICAL AT SCAI 2018

10 March 2018

Learn more about the benefits of OptoWire as a workhorse wire at the Society for Cardiovascular Angiography and Interventions – SCAI 2018 by visiting us at the Opsens booth (#603) or joining us at one of the following: Attend the Poster Session II, “Functional Optimization of Coronary Intervention Using Post-PCI Fractional Flow Reserve: A Prospective…

Read more

SIF 2018 – OPSENS MEDICAL ON EXHIBIT! March 21-24, 2018

27 February 2018

Hear, see and feel the OptoWire® Deux difference at SIF 2018 in Scottsdale, Arizona. Visit the Opsens Medical booth to meet the experts, experience an OptoWire demonstration, and learn more about The OptoWire® One-Wire PCI™ Program!

ATTEND THE OPSENS MEDICAL SPONSORED SYMPOSIUM AT THE CRT 2018 CONFERENCE

19 February 2018

Attend the Opsens sponsored complimentary lunch educational symposium, “Upgrading Coronary Physiologic Approaches: Methods, Myths, and Best Practices” at CRT (Cardiovascular Research Technologies) 2018 Conference in Washington, DC. Opsens offers the first fiber-optic FFR guidewire with nitinol core, providing superior handling, functionality and accuracy, particularly beneficial in complex PCI. Leading experts in coronary physiology will demonstrate clinical utility…

Read more

OPSENS ANNOUNCES ELECTION RESULTS FOR THE BOARD OF DIRECTORS AND THE RETIREMENT OF CLAUDE BELLEVILLE

23 January 2018

  Quebec City, Quebec, January 23, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today held its annual general shareholders’ meeting (the “Meeting”) at its head office in Quebec City, Canada. Opsens’ shareholders re-elected Denis M. Sirois, Denis Harrington, Pat Mackin, Jean Lavigueur, Gaétan Duplain and Louis Laflamme as members of the Board…

Read more

OPSENS REPORTS Q1 2018 RESULTS – RECORD QUARTERLY REVENUES WITH GROWTH IN ALL GEOGRAPHIC REGIONS

16 January 2018

Quebec City, Quebec, January 15, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the first quarter ended November 30, 2017. Highlights Consolidated revenues reached $6,364,000 for Q1 2018 compared with $3,745,000 for the same period last year, an increase of $2,619,000 or 70%; Fractional Flow Reserve (“FFR”) revenues…

Read more

OPSENS’ JAPANESE PARTNER ZEON MEDICAL PROCEEDS WITH CONVERSION OF US$2 MILLION DEBENTURE

27 November 2017

Quebec City, Quebec, November 27, 2017 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) is pleased to announce the conversion of the US$2 million debenture held by Zeon Medical Inc. (“Zeon Medical”), Opsens’ Japanese partner. Zeon Medical has been a client of Opsens since 2004. In 2012, Opsens granted Zeon Medical the exclusive distribution rights for…

Read more